Post-Marketing Authorisation Variations: The changing European regulatory landscape, from regulation to guidance

As of 15 January 2026, the European framework for managing post-marketing authorisation (MA) variations for human medicines has shifted to a new reference standard. Driven by the amendment of Regulation (EC) No 1234/2008 introduced by commission Delegate Regulation (EU)2024/1701—already in force since 1 January 2025—and by the European Commission’s revised guidelines published on 22 September 2025 (ref. C/2025/5045), this evolution represents a decisive milestone: it aims to streamline the classification of variations, harmonise practices across national authorities, and promote a more lifecycle-oriented approach to the management medicinal products.

This article examines how these new regulatory provisions can be leveraged to anticipate, secure, and optimise variation strategies for MA holders.

1. Regulatory framework applicable to post-MA variations 

The European framework governing post-MA variations is based on two complementary instruments: an EU Regulation, which is directly applicable in the Member States, and European Commission guidelines which provide practical guidance for its implementation. 

1.1. Applicable European legislation 

Until recently, the assessment of variations to the terms of MA for human and veterinary medicinal products was governed by Regulation (EC) No 1234/2008, which established the procedures applicable to changes introduced after an MA had been granted.

This framework was amended by Regulation (EU) 2024/1701 of 11 March 2024, which entered into force on 1 January 2025. The new Regulation revises several provisions relating to MA-variation procedures with the aim of strengthening the efficiency and long-term sustainability of lifecycle management for human medicinal products. It also lays the groundwork for certain procedural innovations, such as work-sharing, the “annual update”, and “super-grouping”, which are described below. Its scope is now limited to medicinal products for human use.

1.2. Post-authorisation variation guidelines

Up to and including 14 January 2026, post-authorisation variations were governed by the European Commission guidelines issued in 2013 (2013/C 223/01). These guidelines specifically detailed: 

• The categories of variations (IA, IB and II);
• The assessment procedures set out in Regulation (EC) No 1234/2008;
• The required documentation.

A revised version of these guidelines (C/2025/5045), published on 22 September 2025, entered into force and became mandatory for all variation applications submitted as of 15 January 2026. It now constitutes the reference framework for the classification, preparation and submission of post-authorisation variations at the European level.

This update aims to:

• Increase the efficiency of change management, notably by reducing the administrative burden;
• Improve the predictability of regulatory interactions; and
• Promote the use of tools such as the Post-Approval Change Management Protocol (PACMP) and Product Lifecycle Management (PLCM) documents.

2. New Elements Introduced by the Revised Guidelines

The revised guidelines retain the overall structure of the previous framework while introducing several changes intended to clarify the applicable rules and enhance harmonisation of practices across the European Union (EU). These changes are summarised below.

2.1. Evolution of Variation Typing and Justification

The three variation types – IA, IB and II – remain in place. However, their categorisation has been clarified through a revised coding system, updated conditions, and detailed documentation requirements for each type and category.

The most significant change concerns the restructing of classification categories and their associated codes, particularly for quality variations affecting biological and combination products.

Several categories have been added, refined, or reorganised. Depending on the nature of the change and its justification, certain modifications may now be classified differently compared to the 2013 framework. The new system follows a risk-proportionate approach: changes affecting biological products that were previously  systematically classified as type II, may now, in certain cases, fall into a lower category.

The responsibility for determining the appropriate classification remains with the MA holder, who must provide a robust justification based on the nature of the change and the data submitted.

Variations previously handled as “unforeseen” under Article 5 of the Regulation no longer follow a specific procedure; they are now incorporated into the general variation framework and subject to the same rules on classification, justification and submission.

All variation categories have been reviewed to reflect experience gained and scientific and technological advances. The text highlights the need to update quality documentation whenever the therapeutic indication, dosage regimen, or maximum daily dose is modified.

The guidelines will be updated on a regular basis using an agile approach.

A new coding structure replaces former Chapters A, B, C and D with Chapters E (administrative changes), Q (quality/CMC – Chemistry, Manufacturing and Controls), C (safety, efficacy and pharmacovigilance) and M (plasma master file/vaccine antigen master file procedures). This reorganisation provides a clearer classification based on the nature of the change and represents a significant operational improvement for dossier structuring and variation-management tools.

Together, these adjustments aim to strengthen the consistency of variation dossiers, reduce interpretational differences between authorities, and support more transparent and predictable classification decisions. The guidelines also offer additional detail on the procedures to be followed under the new regulatory framework.

2.2. Management of Type IA Variations: Changes to Submission Procedures

The revised regulatory framework significantly modifies the submission process for type IA variations. Under the new guidelines, individual notification is no longer the default approach: Type IA variations must now be bundled and submitted as part of an annual update.

The annual update consists of a grouped submission covering all Type IA variations relating to the same MA and must be submitted between 9 and 12 months after implementation of the first IA variation. Such grouped IA variations are identified as an “annual update” in the harmonised electronic Application Form (eAF).

Exceptions allowing submission outside the annual update remain limited:

• Type IA IN (Immediate Notification) changes must still be notified without delay.
• In duly justified exceptional circumstances—e.g., supply shortages, public-health emergencies, explicit requests from the authorities, or resubmission of an IA previously rejected within an annual update—an individual filing remains possible.
• When a Type IA variation is submitted together with a Type IB or Type II variation as part of a grouping, provided that the changes are related or that a joint submission is duly justified on regulatory or technical grounds.
• When the variation is included in a “super-grouping,” a specific form of grouping mechanism applicable to type IA affecting several MAs.

Although super-grouping was already used in practice, it is now formally defined in the guidelines. A super-grouping may cover:

• multiple national MAs,
• multiple MRP (Mutual Recognition Procedure) or DCP (Decentralised Procedure) MAs, or
• any combination of national and MRP/DCP MAs,

However, Super-grouping cannot combine centrally authorised products with national or MRP/DCP products  within the same submission.

These changes are intended to reduce the administrative burden associated with minor variations improving traceability and regulatory oversight.

2.3. Work-Sharing now Mandatory

Work-sharing has become mandatory for MA holders. The requirement applies to any submission covering one or more identical changes that affect more than one MA held by the same company and that includes at least one Type IB and/or Type II variation.

The objective is two-fold:

• to prevent multiple competent authorities from evaluating the same change in parallel, and
• to ensure consistent regulatory decisions across the EU.

If a change has already been submitted outside a work-sharing procedure but later falls within its scope, it must be aligned with the work-sharing process to ensure consistent assessment and decision-making across all affected MAs.

2.4. Lifecycle-Based Approach

The revised guidelines adopt a lifecycle-based approach, encouraging earlier and more structured management of post-authorisation changes, particularly for quality aspects. Variations are no longer viewed as isolated modifications but as a part pf a broader lifecycle management  strategy to control and anticipate the evolution of the MA dossier.

Within this context, the revised framework highlights (on an optional basis) several lifecycle-management tools:

• Post-Approval Change Management Protocols (PACMPs) which allow MA holders, in agreement with the authorities, to predefine in advance the strategy, data requirements, and acceptance criteria for certain planned quality changes. A PACMP is submitted and assessed as a Type II variation. Once approved, the subsequent implementation of the change may be notified under a lower variation category than would otherwise apply, thereby streamlining the regulatory handling of future changes.
• Product Lifecycle Management (PLCM) documents serve as planning and tracking tools for quality changes throughout the product lifecycle. They provide a structured record of dossier elements that may evolve and the associated management principles, without altering either the variation categories or the applicable procedures.

To clarify practical implementation, the European Medicines Agency (EMA) has issued dedicated Q&A documents on PACMPs (EMA/CHMP/QWP/586330/2010 Rev. 1) and PLCMs (EMA/CHMP/QWP/7093/2026) between December 2025 and January 2026.

These tools aim to improve anticipation of post-authorisation developments and reinforce the overall coherence of the dossier, while increasing the predictability of regulatory review timelines for certain changes – all without modifying existing variation categories or procedures.

2.5. Harmonisation of Practices at the European Level

The newly revised guidelines build on the existing regulatory framework designed to ensure a harmonised application of variation rules across Europe. They provide additional clarification on regulatory expectations and submission requirements, thereby promoting a more consistent interpretation and implementation of these rules by the competent authorities.

3. Summary of Regulatory Changes Affecting Marketing-Authorisation Variations

In response to the ongoing evolution of the European regulatory framework, several major updates have been adopted to optimise variation management and ensure consistent application across the EU. Key points to remember:

• Amendment of Regulation (EC) No 1234/2008 by Regulation (EU) 2024/1701.
• Replacement of Guidelines 2013/C 223/01 by Guidelines C/2025/5045 as of 15 January 2026, with regular updates planned.
• All variation categories have been re-evaluated in light of accumulated experience and scientific and technical progress; Reassessment of all variation categories under a risk-proportionate approach
• Type IA variations (excluding IAIN) may no longer be submitted individually. They must be bundled in an annual Type IA grouping (“annual update”), unless they are filed within a grouping, a super-grouping, or meet clearly defined exceptions.
• Work-sharing is now mandatory whenever identical changes—including at least one Type IB or Type II variation—affect more than one MA held by the same company.
• Optional use of PACMPs and PLCM documents to support structured lifecycle management of changes. These tools do not replace existing variation procedures.

Need support?

Efor’s Regulatory Affairs teams assist pharmaceutical companies in understanding and applying regulatory requirements throughout the lifecycle of medicinal products, with a particular focus on post-authorisation variations. In light of these new developments described above, Efor can help MA holders to:

• Analyse the impact of the latest provisions,
• Adapt variation-management strategies,
• Secure the operational implementation of changes.

To discuss your needs and design the most appropriate support strategy for your variation projects and regulatory challenges, please contact us at solutionprojectdelivery@efor-group.com.